JP2017532285A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532285A5 JP2017532285A5 JP2016549442A JP2016549442A JP2017532285A5 JP 2017532285 A5 JP2017532285 A5 JP 2017532285A5 JP 2016549442 A JP2016549442 A JP 2016549442A JP 2016549442 A JP2016549442 A JP 2016549442A JP 2017532285 A5 JP2017532285 A5 JP 2017532285A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- bcl
- nutrin
- inhibiting
- mdm2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 230000002401 inhibitory effect Effects 0.000 claims 22
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims 16
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 16
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims 13
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 12
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 12
- -1 Serdemethan Chemical compound 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 208000019693 Lung disease Diseases 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 150000003384 small molecules Chemical class 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000030533 eye disease Diseases 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 5
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims 4
- CLRSLRWKONPSRQ-IIPSPAQQSA-N C1([C@@H]2N(C(=O)CC=3C=C(C(=CC=32)OC(C)C)OC)C=2C=CC(=CC=2)N(C)C[C@@H]2CC[C@H](CC2)N2CC(=O)N(C)CC2)=CC=C(Cl)C=C1 Chemical compound C1([C@@H]2N(C(=O)CC=3C=C(C(=CC=32)OC(C)C)OC)C=2C=CC(=CC=2)N(C)C[C@@H]2CC[C@H](CC2)N2CC(=O)N(C)CC2)=CC=C(Cl)C=C1 CLRSLRWKONPSRQ-IIPSPAQQSA-N 0.000 claims 4
- 230000032683 aging Effects 0.000 claims 4
- 201000008482 osteoarthritis Diseases 0.000 claims 4
- 208000022873 Ocular disease Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 230000003349 osteoarthritic effect Effects 0.000 claims 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 2
- SOYCFODXNRVBTI-UHFFFAOYSA-N 2-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]-2-fluorophenoxy]propyl]-1,3-thiazole-4-carboxylic acid Chemical compound FC1=CC(C#CCN(C)C)=CC=C1OCCCC1=C(C(O)=O)N=C(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)S1 SOYCFODXNRVBTI-UHFFFAOYSA-N 0.000 claims 2
- JKMWZKPAXZBYEH-JWHWKPFMSA-N 5-[3-[4-(aminomethyl)phenoxy]propyl]-2-[(8e)-8-(1,3-benzothiazol-2-ylhydrazinylidene)-6,7-dihydro-5h-naphthalen-2-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(CN)=CC=C1OCCCC1=C(C(O)=O)N=C(C=2C=C3C(=N/NC=4SC5=CC=CC=C5N=4)/CCCC3=CC=2)S1 JKMWZKPAXZBYEH-JWHWKPFMSA-N 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 150000003927 aminopyridines Chemical class 0.000 claims 2
- 229940049706 benzodiazepine Drugs 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 claims 2
- 125000006502 nitrobenzyl group Chemical group 0.000 claims 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims 2
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 102000000503 Collagen Type II Human genes 0.000 claims 1
- 108010041390 Collagen Type II Proteins 0.000 claims 1
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000000795 conjunctiva Anatomy 0.000 claims 1
- 239000003405 delayed action preparation Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000002431 foraging effect Effects 0.000 claims 1
- 210000004220 fundus oculi Anatomy 0.000 claims 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims 1
- 229940099552 hyaluronan Drugs 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 210000000229 preadipocyte Anatomy 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000009758 senescence Effects 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002627 tracheal intubation Methods 0.000 claims 1
Applications Claiming Priority (23)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461932711P | 2014-01-28 | 2014-01-28 | |
| US201461932704P | 2014-01-28 | 2014-01-28 | |
| US61/932,711 | 2014-01-28 | ||
| US61/932,704 | 2014-01-28 | ||
| US201461979911P | 2014-04-15 | 2014-04-15 | |
| US61/979,911 | 2014-04-15 | ||
| US201462002709P | 2014-05-23 | 2014-05-23 | |
| US62/002,709 | 2014-05-23 | ||
| US201462042708P | 2014-08-27 | 2014-08-27 | |
| US62/042,708 | 2014-08-27 | ||
| US201462044664P | 2014-09-02 | 2014-09-02 | |
| US62/044,664 | 2014-09-02 | ||
| US201462057820P | 2014-09-30 | 2014-09-30 | |
| US201462057825P | 2014-09-30 | 2014-09-30 | |
| US201462057828P | 2014-09-30 | 2014-09-30 | |
| US62/057,828 | 2014-09-30 | ||
| US62/057,825 | 2014-09-30 | ||
| US62/057,820 | 2014-09-30 | ||
| US201462061629P | 2014-10-08 | 2014-10-08 | |
| US201462061627P | 2014-10-08 | 2014-10-08 | |
| US62/061,629 | 2014-10-08 | ||
| US62/061,627 | 2014-10-08 | ||
| PCT/US2015/013387 WO2015116740A1 (en) | 2014-01-28 | 2015-01-28 | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019083555A Division JP2019142933A (ja) | 2014-01-28 | 2019-04-25 | 病変した組織から老化細胞を除去することにより眼の疾患、肺の疾患またはアテローム性動脈硬化を処置するための医薬 |
| JP2020038529A Division JP2020105213A (ja) | 2014-01-28 | 2020-03-06 | 病変した組織から老化細胞を除去することにより眼の疾患、肺の疾患またはアテローム性動脈硬化を処置するための医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532285A JP2017532285A (ja) | 2017-11-02 |
| JP2017532285A5 true JP2017532285A5 (cg-RX-API-DMAC7.html) | 2018-03-08 |
| JP6688224B2 JP6688224B2 (ja) | 2020-04-28 |
Family
ID=53757701
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549442A Expired - Fee Related JP6688224B2 (ja) | 2014-01-28 | 2015-01-28 | Ｍｄｍ２を阻害する手段の投与による関節における変形性関節症の処置 |
| JP2019083555A Pending JP2019142933A (ja) | 2014-01-28 | 2019-04-25 | 病変した組織から老化細胞を除去することにより眼の疾患、肺の疾患またはアテローム性動脈硬化を処置するための医薬 |
| JP2020038529A Withdrawn JP2020105213A (ja) | 2014-01-28 | 2020-03-06 | 病変した組織から老化細胞を除去することにより眼の疾患、肺の疾患またはアテローム性動脈硬化を処置するための医薬 |
| JP2021081356A Pending JP2021138712A (ja) | 2014-01-28 | 2021-05-13 | 老化細胞を殺し、老化関連疾患および障害を処置するための方法と組成物 |
| JP2023110762A Pending JP2023126918A (ja) | 2014-01-28 | 2023-07-05 | 老化細胞を殺し、老化関連疾患および障害を処置するための方法と組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019083555A Pending JP2019142933A (ja) | 2014-01-28 | 2019-04-25 | 病変した組織から老化細胞を除去することにより眼の疾患、肺の疾患またはアテローム性動脈硬化を処置するための医薬 |
| JP2020038529A Withdrawn JP2020105213A (ja) | 2014-01-28 | 2020-03-06 | 病変した組織から老化細胞を除去することにより眼の疾患、肺の疾患またはアテローム性動脈硬化を処置するための医薬 |
| JP2021081356A Pending JP2021138712A (ja) | 2014-01-28 | 2021-05-13 | 老化細胞を殺し、老化関連疾患および障害を処置するための方法と組成物 |
| JP2023110762A Pending JP2023126918A (ja) | 2014-01-28 | 2023-07-05 | 老化細胞を殺し、老化関連疾患および障害を処置するための方法と組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (19) | US9993472B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3669881B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP6688224B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102496146B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN112274641A (cg-RX-API-DMAC7.html) |
| AU (4) | AU2015211021B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016017564A8 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3100140C (cg-RX-API-DMAC7.html) |
| IL (3) | IL311537A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2016009753A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ723035A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2716256C2 (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201606239UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015116740A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2789684T3 (en) | 2008-05-23 | 2017-02-20 | Siwa Corp | Methods and compositions for facilitating regeneration |
| US9649376B2 (en) | 2010-09-27 | 2017-05-16 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
| US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| SG11201606239UA (en) | 2014-01-28 | 2016-08-30 | Buck Inst For Res On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| CN106456699B (zh) | 2014-05-05 | 2021-07-02 | 生物风险投资有限责任公司 | 作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法 |
| US10258639B2 (en) * | 2014-05-06 | 2019-04-16 | Research Development Foundation | Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy |
| WO2016014625A1 (en) | 2014-07-22 | 2016-01-28 | Board Of Trustees Of The University Of Arkansas | Compositions and methods for selectively depleting senescent cells |
| EP3194439B1 (en) | 2014-09-19 | 2022-01-19 | Siwa Corporation | Anti-age antibodies for treating inflammation and auto-immune disorders |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| CA2981753A1 (en) * | 2015-02-06 | 2016-08-11 | Unity Biotechnology, Inc. | Compounds and uses in treatment of senescence-associated conditions |
| EP3261612A1 (en) * | 2015-02-26 | 2018-01-03 | Yeda Research and Development Co. Ltd | Method of promoting hair growth |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| WO2017002120A1 (en) * | 2015-07-02 | 2017-01-05 | Yeda Research And Development Co. Ltd. | Selective inhibitors of senescent cells and uses thereof |
| WO2017101851A1 (en) * | 2015-12-18 | 2017-06-22 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
| JP6722293B2 (ja) | 2016-02-19 | 2020-07-15 | シワ コーポレーション | 終末糖化産物（ａｇｅ）に対する抗体を使用して、がんを治療、転移性がん細胞を殺傷、及びがん転移を予防するための方法及び組成物 |
| KR102511028B1 (ko) | 2016-03-15 | 2023-03-16 | 오리존 지노믹스 에스.에이. | 혈액 악성 종양의 치료를 위한 lsd1 억제제의 조합물 |
| CA3057829A1 (en) | 2016-04-15 | 2017-10-19 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
| EP3445452A4 (en) | 2016-04-21 | 2019-10-30 | BioVentures, LLC | COMPOUNDS FOR INDUCING THE DEGRADATION OF ANTIAPOPTOTIC PROTEINS OF THE BCL-2 FAMILY AND USES THEREOF |
| US20190054097A1 (en) * | 2016-04-21 | 2019-02-21 | Bioventures, Llc | Compositions targeting senescent cells and the uses thereof |
| WO2017223107A1 (en) * | 2016-06-20 | 2017-12-28 | Unity Biotechnology, Inc. | Genome modifying enzyme therapy for diseases modulated by senescent cells |
| US11213585B2 (en) | 2016-06-23 | 2022-01-04 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
| US10174018B2 (en) | 2016-12-13 | 2019-01-08 | Princeton Drug Discovery Inc | Protein kinase inhibitors |
| MX2019007981A (es) | 2017-01-03 | 2019-10-15 | Bioatla Llc | Terapeutica de proteinas para el tratamiento de celulas senescentes. |
| US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
| US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
| US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
| US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
| US20200041492A1 (en) | 2017-03-09 | 2020-02-06 | Rijksuniversiteit Groningen | Biomarkers for cellular senescence |
| EP3609923A1 (en) | 2017-04-13 | 2020-02-19 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| TWI651087B (zh) * | 2017-04-21 | 2019-02-21 | Chang Gung University | 類泛素化抑制劑於預防或治療骨質疏鬆症的用途 |
| CA3062082A1 (en) * | 2017-05-04 | 2018-11-08 | Siwa Corporation | Diagnostic advanced glycation end-product antibodies |
| AU2018202878A1 (en) * | 2017-05-16 | 2018-12-06 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| US11413280B2 (en) * | 2017-05-19 | 2022-08-16 | The Board Of Trustees Of The Leland Stanford Junior University | Enzastaurin and fragile histidine triad (FHIT)-increasing agents for the treatment of pulmonary hypertension |
| GB201708456D0 (en) * | 2017-05-26 | 2017-07-12 | Medical Res Council | Senolytic compounds |
| US20180344865A1 (en) * | 2017-05-31 | 2018-12-06 | Palo Alto Investors | Methods of Increasing Fertility in a Female Subject |
| KR20200035944A (ko) | 2017-06-16 | 2020-04-06 | 유니티 바이오테크놀로지, 인크. | 약제학적 용도를 위해 에난티오머적으로 순수한 시스-이미다졸린 화합물을 제조하기 위한 합성 방법 |
| EP4234025A3 (en) | 2017-08-11 | 2024-04-24 | Unity Biotechnology, Inc. | Treatment of diabetic retinopathy using pharmaceutical agents that eliminate senescent cells |
| US20200354336A9 (en) | 2017-08-11 | 2020-11-12 | Unity Biotechnology, Inc. | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells |
| JP7370599B2 (ja) * | 2017-10-06 | 2023-10-30 | バック・インスティテュート・フォー・リサーチ・オン・エイジング | 老化細胞のためのバイオマーカー |
| US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| US20200360386A1 (en) * | 2017-12-30 | 2020-11-19 | Unity Biotechnology, Inc. | Inhibitors of HSP90, PI3-Kinase, Proteasome, HDAC, and P97 Pathways for Selective Removal of Senescent Cells in the Treatment of Age Related Conditions |
| EP3548504B1 (en) | 2017-12-30 | 2021-07-21 | Unity Biotechnology, Inc. | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
| US10689416B2 (en) | 2017-12-30 | 2020-06-23 | Unity Biotechnology, Inc. | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
| CA3088253A1 (en) | 2018-01-22 | 2019-07-25 | Bioventures, Llc | Bcl-2 proteins degraders for cancer treatment |
| CN112136048A (zh) * | 2018-02-21 | 2020-12-25 | 艾迪菲斯健康有限公司 | 测量全身性慢性炎性衰老的方法 |
| WO2019183282A1 (en) * | 2018-03-21 | 2019-09-26 | Mayo Foundation For Medical Education And Research | Senolytic agents for the treatment of tauopathies |
| WO2019198091A1 (en) | 2018-04-12 | 2019-10-17 | Yeda Research And Development Co. Ltd. | Blood based treatment |
| US10738042B2 (en) | 2018-04-30 | 2020-08-11 | Unity Biotechnology, Inc. | Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| CA3056878C (en) | 2018-04-30 | 2021-03-30 | Unity Biotechnology | Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| IL319432A (en) * | 2018-04-30 | 2025-05-01 | Kartos Therapeutics Inc | Methods of treating cancer |
| WO2019213160A1 (en) | 2018-04-30 | 2019-11-07 | Unity Biotechnology | Acyl phosphonamidates and acyl benzylamines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| JP7402225B2 (ja) | 2018-05-11 | 2023-12-20 | ロード アイランド ホスピタル | ヌクレオシド系逆転写酵素阻害剤を用いて関節障害を処置するための組成物および方法 |
| WO2019221755A1 (en) | 2018-05-18 | 2019-11-21 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| MX2020012637A (es) * | 2018-05-24 | 2021-04-28 | Renibus Therapeutics Inc | Metodos de tratamiento para pacientes con riesgo de lesion e insuficiencia renal. |
| US11003537B2 (en) | 2018-05-29 | 2021-05-11 | Micron Technology, Inc. | Determining validity of data read from memory by a controller |
| US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| EP3809983B1 (en) | 2018-06-22 | 2025-08-27 | Mayo Foundation for Medical Education and Research | Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality |
| WO2020014409A1 (en) | 2018-07-11 | 2020-01-16 | Rubedo Life Sciences, Inc. | Senolytic compositions and uses thereof |
| JP7557463B2 (ja) * | 2018-07-20 | 2024-09-27 | エフ． ホフマン－ラ ロシュ アーゲー | Ｉｇｆｂｐ－７に基づく妊娠高血圧腎症の予測 |
| CN109406764B (zh) * | 2018-09-13 | 2022-02-01 | 中国辐射防护研究院 | 腹腔放疗后药物体内过程评价动物模型的建立与评价方法 |
| JP7460639B2 (ja) * | 2018-09-18 | 2024-04-02 | シグナルケム・ライフサイエンシーズ・コーポレイション | 血液癌を治療するための併用療法 |
| WO2020119614A1 (en) * | 2018-12-14 | 2020-06-18 | Ascentage Pharma (Suzhou) Co., Ltd. | A compound for treating osteoarthritis |
| WO2020132053A1 (en) * | 2018-12-20 | 2020-06-25 | Mayo Foundation For Medical Education And Research | Methods and materials for treating neuropsychiatric disorders |
| WO2020150394A1 (en) * | 2019-01-15 | 2020-07-23 | The Johns Hopkins University | Regulation of a foreign body response |
| FR3091864B1 (fr) | 2019-01-20 | 2022-07-29 | Waterdiam France | Eau électrolysée, procédé d’obtention et utilisations d’une telle eau pour le traitement de désordres liés à la sénescence cellulaire |
| SG11202107145SA (en) | 2019-01-25 | 2021-08-30 | Univ Brown | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
| CN111494366A (zh) * | 2019-01-31 | 2020-08-07 | 洛阳尚德药缘科技有限公司 | 二甲基氨基含笑内酯在制备抗衰老药物上的应用 |
| CN110161226A (zh) * | 2019-02-27 | 2019-08-23 | 杭州晟康细胞生物科技有限公司 | 一种检测衰老细胞用的抗体、试剂盒及检测方法 |
| EP3705109A1 (en) | 2019-03-05 | 2020-09-09 | Greenaltech, S.L. | Carotenoids in the treatment of senescence-related diseases |
| ES3044861T3 (en) | 2019-03-20 | 2025-11-27 | Juntendo Educational Found | Agent targeting double-membrane organelle dna |
| CA3130706A1 (en) | 2019-04-04 | 2020-10-08 | Dana-Farber Cancer Institute, Inc. | Cdk2/5 degraders and uses thereof |
| JP2022536653A (ja) * | 2019-06-10 | 2022-08-18 | バック インスティチュート フォー リサーチ オン エージング | 老化関連分泌表現型を修整する方法および組成物 |
| WO2020257173A1 (en) * | 2019-06-17 | 2020-12-24 | Unity Biotechnology, Inc. | Method of treating the osteoarthritic joint |
| CN111407884B (zh) * | 2019-06-24 | 2021-12-07 | 浙江大学 | 促生长激素释放激素激动剂ghrh-a在制备抗衰老药物中的用途 |
| CN110934873B (zh) * | 2019-08-22 | 2022-10-28 | 中国科学院上海营养与健康研究所 | 靶向组织微环境中衰老细胞的抗衰老药物d/s及其应用 |
| WO2021078301A1 (zh) * | 2019-10-24 | 2021-04-29 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| BR112022008683A2 (pt) | 2019-11-05 | 2022-07-19 | Abbvie Inc | Regimes de dosagem para uso no tratamento de mielofibrose e distúrbios relacionados a mpn com navitoclax |
| EP4069723A4 (en) * | 2019-12-02 | 2024-05-15 | Viome Life Sciences, Inc. | Detection and elimination of aberrant cells |
| AU2021207672A1 (en) | 2020-01-15 | 2022-07-14 | University Of Florida Research Foundation, Incorporated | Therapeutic agents and methods of treatment |
| WO2021188948A1 (en) | 2020-03-19 | 2021-09-23 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
| JP2023522979A (ja) * | 2020-04-23 | 2023-06-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｉＮＫＴ細胞の活性化による老化細胞の排除 |
| EP4157204A4 (en) * | 2020-06-02 | 2024-09-04 | Buck Institute for Research on Aging | Dihomo-gamma linolenic acid (dgla) is a novel senolytic |
| EP4168436A4 (en) * | 2020-06-17 | 2024-07-31 | Mayo Foundation for Medical Education and Research | EVALUATION AND TREATMENT OF BIOLOGICAL AGING |
| CN111973578A (zh) * | 2020-08-03 | 2020-11-24 | 天津医科大学 | C188-9、Venetoclax、Bumetanide在纤维化疾病药物中的应用 |
| KR20220056730A (ko) * | 2020-10-28 | 2022-05-06 | 의료법인 성광의료재단 | Abt263을 유효성분으로 포함하는 디스크 질환 예방 및 치료용 조성물 |
| CN112294962B (zh) * | 2020-11-13 | 2023-06-06 | 上海长海医院 | Bcl-2及bcl-xl抑制剂在瘢痕治疗中的应用 |
| CN112891358B (zh) * | 2020-11-19 | 2023-05-12 | 苏州正永生物医药有限公司 | Bcl-2抑制剂的应用及治疗衰老相关皮肤病的药物组合物 |
| WO2022138700A1 (ja) * | 2020-12-23 | 2022-06-30 | ピアス株式会社 | アトピー性皮膚疾患改善剤、皮膚外用剤、及び、化粧料 |
| EP4284390A4 (en) * | 2021-01-29 | 2025-10-29 | Alnylam Pharmaceuticals Inc | ARNI COMPOSITIONS AND METHODS FOR SILENCER OF AMYLOID PRECURSOR PROTEIN (APP) |
| KR102625248B1 (ko) * | 2021-05-04 | 2024-01-16 | 주식회사 퓨전바이오텍 | 이미다졸린 유도체 화합물을 유효성분으로 포함하는 황반 변성 치료용 약학적 조성물 |
| CN113341126A (zh) * | 2021-05-07 | 2021-09-03 | 中国科学院动物研究所 | 一种评价或辅助评价海马组织衰老的标志物 |
| US20240342121A1 (en) * | 2021-07-09 | 2024-10-17 | Georgia State University Research Foundation, Inc. | The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections |
| CN113509555B (zh) * | 2021-07-19 | 2022-05-03 | 中国药科大学 | Akt2抑制剂在制备非酒精性脂肪肝病治疗药物中的应用 |
| EP4387565A4 (en) * | 2021-08-20 | 2025-07-16 | The Brain Prot Company Pty Ltd | COMBINATION THERAPIES INCLUDING IMPLANTABLE CUSHIONING DEVICES AND THERAPEUTIC AGENTS FOR TREATING A PATHOLOGY AND RELATED SYSTEMS AND METHODS OF USE |
| EP4388016A1 (en) | 2021-08-20 | 2024-06-26 | Siwa Corporation | Methods and compositions for treating fibrotic diseases |
| CN113694071B (zh) * | 2021-08-31 | 2025-08-15 | 上海交通大学医学院附属瑞金医院 | 清除和/或溶解衰老细胞和/或抑制细胞衰老的化合物用于治疗精神障碍 |
| EP4380945A4 (en) | 2021-09-13 | 2025-07-09 | Rubedo Life Sciences Inc | NOVEL SUGAR DERIVATIVES AND THEIR USES FOR PREPARING NOVEL SENOLYTIC AGENTS |
| EP4380575A4 (en) * | 2021-09-13 | 2025-07-23 | Rubedo Life Sciences Inc | DRUG CONJUGATES OF SUGAR DERIVATIVES AND THEIR USES AS SENOLYTIC AGENTS |
| WO2023064326A1 (en) * | 2021-10-12 | 2023-04-20 | University Of Florida Research Foundation, Incorporated | Methods of treating diseases associated with senescent cell accumulation |
| KR20230080336A (ko) * | 2021-11-29 | 2023-06-07 | 에스케이케미칼 주식회사 | 오바토클락스 대사성 질환 및 섬유화 질환 치료 용도 |
| WO2023146979A1 (en) * | 2022-01-27 | 2023-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | A single cell mass cytometry platform to map the effects of candidate agents on cartilage |
| KR102879114B1 (ko) * | 2022-03-29 | 2025-11-05 | 주식회사 퓨전바이오텍 | 당 결합된 이미다졸린 유도체 및 이의 용도 |
| WO2023191513A1 (ko) * | 2022-03-29 | 2023-10-05 | 주식회사 퓨전바이오텍 | 당 결합된 이미다졸린 유도체 및 이의 용도 |
| JP2025520155A (ja) * | 2022-06-01 | 2025-07-01 | センス リサーチ ファウンデーション | ガンマデルタｔ細胞による老化細胞の標的除去 |
| KR20250029225A (ko) | 2022-07-01 | 2025-03-04 | 제이제이알앤디 엘엘씨 | 화학 요법 유발된 탈모증의 예방 및 치료 방법 |
| WO2024039646A1 (en) * | 2022-08-15 | 2024-02-22 | Mayo Foundation For Medical Education And Research | Methods and materials for using and assessing anti-senescence treatments within mammals |
| CN118063438A (zh) * | 2022-11-14 | 2024-05-24 | 北京华益健康药物研究中心 | Mdm2/mdmx双靶点抑制剂化合物、前药、药物组合物及其制备方法和应用 |
| WO2024229271A1 (en) * | 2023-05-03 | 2024-11-07 | Memorial Sloan-Kettering Cancer Center | Nanoparticle-based theranostic platform for diagnosis and treatment of senescence-related pathologies |
| WO2025054580A1 (en) * | 2023-09-08 | 2025-03-13 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Compositions and methods for increasing myocardial capillary formation, reducing left ventricular hypertrophy and/or reducing ventricular dysfunction |
| WO2025096949A1 (en) * | 2023-11-03 | 2025-05-08 | Taiwan Liposome Company, Ltd. | Liposomal composition of intra-articular corticosteroid for pain control |
| WO2025117556A1 (en) * | 2023-11-27 | 2025-06-05 | Rubedo Life Sciences, Inc. | Phosphorous containing bcl inhibitors and senolytic compounds and uses thereof |
Family Cites Families (161)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1021342A (en) | 1910-04-20 | 1912-03-26 | James D Swindell | Furnace. |
| US1025861A (en) | 1911-12-12 | 1912-05-07 | John Martin Case | Train-order holder. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| RU2128709C1 (ru) | 1992-01-23 | 1999-04-10 | Мерк Патент Гмбх | Способ получения димерного одноцепочечного слитого белка (варианты) |
| AU4769893A (en) | 1992-07-17 | 1994-02-14 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
| US5700638A (en) | 1993-08-26 | 1997-12-23 | Washington University | Cell death regulator |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| DE69718341T2 (de) | 1996-10-08 | 2003-10-30 | U-Bisys B.V., Utrecht | Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül |
| IL129951A0 (en) | 1997-07-02 | 2000-02-29 | Euro Celtique Sa | Prolonged anesthesia in joints and body spaces |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| DE69941447D1 (de) | 1998-01-05 | 2009-11-05 | Univ Washington | Erhöhter transport unter benutzung membranzerstörender stoffe |
| US20020197602A1 (en) | 1998-04-15 | 2002-12-26 | Glenna C. Burmer | Nucleic acid sequences and proteins associated with aging |
| US6664443B1 (en) | 1998-05-01 | 2003-12-16 | Mayo Foundation For Medical Education And Research | Pathogenic Tau mutations in transgenic mice |
| US20020068704A1 (en) | 1999-04-05 | 2002-06-06 | Ziegler Randy H. | Compositions and methods for treatment of diabetes |
| GB9910119D0 (en) | 1999-04-30 | 1999-06-30 | Novartis Ag | Organic compounds |
| IT1317846B1 (it) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
| US6656461B1 (en) | 2000-02-29 | 2003-12-02 | The Trustees Of Columbia University In The City Of New York | Therapeutic treatment of chronic obstructive pulmonary disease |
| AR031130A1 (es) | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| EP1417976A4 (en) | 2001-07-26 | 2004-09-15 | Santen Pharmaceutical Co Ltd | AGENT FOR TREATING GLAUKOM WITH A COMPOUND WITH PI3-KINASE INHIBITING EFFECT |
| WO2003028443A1 (en) | 2001-09-28 | 2003-04-10 | The Walter And Eliza Hall Institute Of Medical Research | Screening methods for agents that modulate degenerative disorders associated with bcl-2-and bim |
| US20030086916A1 (en) | 2001-10-12 | 2003-05-08 | Goligorsky Michael S. | Use of peroxynitrite scavengers or peroxynitrite formation inhibitors that do not diminish nitric oxide synthesis or activity to reverse or prevent premature vascular senescence |
| DE60227108D1 (de) | 2001-12-18 | 2008-07-24 | Hoffmann La Roche | Cis-imidazoline als mdm2-hemmer |
| RU2305095C2 (ru) | 2001-12-18 | 2007-08-27 | Ф.Хоффманн-Ля Рош Аг | Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе |
| AU2002303023A1 (en) | 2002-06-05 | 2003-12-22 | Metabolic Engineering Laboratories Co., Ltd. | Signals and molecular species involved in senescence |
| FI117094B (fi) * | 2003-01-15 | 2006-06-15 | Fractivator Oy | Menetelmä orgaanisen jätteen hajottamiseksi |
| PL1641916T3 (pl) * | 2003-06-27 | 2016-08-31 | Depuy Synthes Products Inc | Regeneracja i naprawa tkanki nerwowej z wykorzystaniem komórek poporodowych |
| CA2535920C (en) * | 2003-08-29 | 2009-06-23 | Kowa Co., Ltd. | Method of stabilizing lipid-rich plaque and method of preventing rupture thereof |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US20060182781A1 (en) | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| GB0411166D0 (en) | 2004-05-19 | 2004-06-23 | Bionovate Ltd | Treatment for asthma and arthritis |
| US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| US7851637B2 (en) | 2004-06-17 | 2010-12-14 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| US7842815B2 (en) | 2004-06-17 | 2010-11-30 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| GB0418388D0 (en) | 2004-08-18 | 2004-09-22 | Univ Newcastle | Cell therapy |
| WO2006039704A2 (en) * | 2004-09-30 | 2006-04-13 | Janssen Pharmaceutica, N.V. | Pharmaceutical composition and method for treating a joint capsule arthropathy |
| US8624027B2 (en) * | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| CN101175738B (zh) | 2005-05-12 | 2010-10-27 | 雅培制药有限公司 | 细胞凋亡促进剂 |
| WO2006127364A1 (en) | 2005-05-24 | 2006-11-30 | Abbott Laboratories | Apoptosis promoters |
| JP4870778B2 (ja) | 2005-12-01 | 2012-02-08 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ガン剤として使用されるｐ５３およびｍｄｍ２タンパク質間の相互作用の阻害剤としての２，４，５−トリフェニルイミダゾリン誘導体 |
| PL1959925T3 (pl) | 2005-12-02 | 2017-05-31 | (Osi) Eyetech, Inc. | Mikrocząstki o kontrolowanym uwalnianiu |
| BRPI0710477A2 (pt) | 2006-01-18 | 2011-08-16 | Hoffmann La Roche | cis-4, 5- biarila - 2- imidazolinas heterocìclicas como inibidores da mdm2 |
| US8470785B2 (en) | 2006-07-28 | 2013-06-25 | St. Jude Children's Research Hospital | Method for treating ocular cancer |
| WO2008014216A1 (en) * | 2006-07-28 | 2008-01-31 | St. Jude Children's Research Hospital | Method for treating ocular cancer |
| US20100292200A1 (en) | 2006-08-11 | 2010-11-18 | The Walter And Eliza Hall Institute Of Medical Research | Methods for Modulating Apoptosis in Platelets |
| EA016145B1 (ru) * | 2006-08-30 | 2012-02-28 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Новые низкомолекулярные ингибиторы mdm2 и их применение |
| CN101534904B (zh) | 2006-09-05 | 2013-11-06 | Abbvie公司 | 治疗血小板过量的bcl抑制剂 |
| US20080221132A1 (en) | 2006-09-11 | 2008-09-11 | Xiong Cai | Multi-Functional Small Molecules as Anti-Proliferative Agents |
| CN101641338A (zh) * | 2006-09-11 | 2010-02-03 | 柯瑞斯公司 | 作为抗增殖制剂的多功能小分子 |
| CN101535280B (zh) | 2006-11-15 | 2012-06-27 | 健泰科生物技术公司 | 芳基磺酰胺化合物 |
| US20100087436A1 (en) | 2006-11-16 | 2010-04-08 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| US20080125487A1 (en) * | 2006-11-17 | 2008-05-29 | Tapas Das | Elongase gene and uses thereof |
| AR064010A1 (es) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | Inhibidores de la actividad de la akt |
| WO2008106507A2 (en) * | 2007-02-27 | 2008-09-04 | University Of South Florida | Mdm2/mdmx inhibitor peptide |
| WO2008113131A1 (en) | 2007-03-20 | 2008-09-25 | The Walter And Eliza Hall Institute Of Medical Research | Method of screening |
| CA2682483A1 (en) * | 2007-03-29 | 2008-10-09 | Novartis Ag | 3-imidazolyl-indoles for the treatment of proliferative diseases |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| US20090118135A1 (en) | 2007-06-08 | 2009-05-07 | The Burnham Institute | Methods and compounds for regulating apoptosis |
| US20110028437A1 (en) | 2007-07-31 | 2011-02-03 | Limerick Biopharma, Inc. | Phosphorylated pyrone analogs and methods |
| US8283160B2 (en) | 2007-09-11 | 2012-10-09 | Frey Ii William H | Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system |
| WO2009042798A1 (en) * | 2007-09-26 | 2009-04-02 | Cold Spring Harbor Laboratory | Methods for treating fibrosis by modulating cellular senescence |
| AU2007359392A1 (en) | 2007-09-27 | 2009-04-02 | The Walter And Eliza Hall Institute Of Medical Research | Benzothiazole compounds |
| JP2011502963A (ja) | 2007-10-19 | 2011-01-27 | バーンハム インスティテュート フォー メディカル リサーチ | 抗アポトーシスタンパク質であるナフタレン系阻害剤 |
| US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
| WO2009105234A2 (en) | 2008-02-19 | 2009-08-27 | Combinatorx, Incorporated | Methods and compositions for the treatment of disorders associated with defects of the cystic fibrosis transmembrane conductance regulator gene or protein |
| WO2009117018A1 (en) | 2008-03-20 | 2009-09-24 | Transmolecular, Inc. | Inhibition of angiogenesis |
| WO2009120186A1 (en) | 2008-03-24 | 2009-10-01 | Carolus Therapeutics, Inc. | Methods and compositions for treating atherosclerosis and related conditions |
| US7782903B2 (en) | 2008-05-14 | 2010-08-24 | Newport Media, Inc. | Hardware accelerated protocol stack |
| DK2789684T3 (en) | 2008-05-23 | 2017-02-20 | Siwa Corp | Methods and compositions for facilitating regeneration |
| EP2298778A4 (en) | 2008-06-12 | 2011-10-05 | Daiichi Sankyo Co Ltd | IMIDAZOTHIAZOL DERIVATIVE WITH 4,7-DIAZASPIRO [2.5] OCTAN RING STRUCTURE |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| JP5491502B2 (ja) | 2008-07-14 | 2014-05-14 | オトノミ―，インク． | 制御放出アポトーシス調節化合物および耳の障害の処置のための方法 |
| US20100093648A1 (en) | 2008-10-09 | 2010-04-15 | Antonio Cruz | Treatment of macular degeneration-related disorders |
| CN101507729B (zh) * | 2008-10-23 | 2010-12-22 | 昆明诺唯金参生物工程有限责任公司 | 人参皂苷Compound K在制备防治动脉粥样硬化的药物中的应用 |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| WO2010068684A2 (en) * | 2008-12-09 | 2010-06-17 | Dana Farber Cancer Institute, Inc. | Methods and compositions for specific modulation of mcl-1 |
| BRPI0918337A2 (pt) | 2008-12-19 | 2017-05-30 | Abbott Lab | composto, composição farmacêutica, método de tratamento, método para tratar uma doença ou condição causada, exacerbada ou resultante de um excesso de plaquetas ou ativação indesejada de plaquetas em um paciente, método para reduzir a contagem de plaquetas circulantes em um paciente e uso |
| US20130302283A1 (en) | 2012-05-14 | 2013-11-14 | Advanced Technologies And Regenerative Medicine, Llc | hUTC MODULATION OF PRO-INFLAMMATORY MEDIATORS OF LUNG AND PULMONARY DISEASES AND DISORDERS |
| EP2373163B1 (en) | 2008-12-19 | 2015-06-10 | Genentech, Inc. | Heterocyclic compounds and methods of use |
| MX2011007681A (es) | 2009-01-19 | 2011-08-08 | Abbott Lab | Agentes inducidores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes. |
| US20120046333A1 (en) * | 2009-04-09 | 2012-02-23 | Oncothyreon Incorporated | Methods and Compositions of PI-3 Kinase Inhibitors for Treating Fibrosis |
| WO2010118419A2 (en) | 2009-04-10 | 2010-10-14 | Haiyan Qi | Novel anti-aging agents and methods to identify them |
| US8362013B2 (en) * | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2010148447A1 (en) | 2009-06-23 | 2010-12-29 | Centenary Institute Of Cancer Medicine And Cell Biology | A novel regulator of cellular senescence |
| AU2010295717B2 (en) * | 2009-09-20 | 2014-09-11 | Abbvie Inc. | ABT-263 crystalline forms and solvates for use in treating Bcl-2 protein related diseases |
| US8859776B2 (en) | 2009-10-14 | 2014-10-14 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
| US20120283269A1 (en) | 2009-11-04 | 2012-11-08 | Health Research Inc. | Method and Compositions for Suppression of Aging |
| TW201127384A (en) | 2009-11-18 | 2011-08-16 | Nerviano Medical Sciences Srl | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent |
| US8658170B2 (en) | 2010-01-06 | 2014-02-25 | Joseph P. Errico | Combination therapy with MDM2 and EFGR inhibitors |
| EP2633884A1 (en) | 2010-01-07 | 2013-09-04 | Akron Molecules GmbH | Obesity small molecules |
| WO2011098262A2 (en) | 2010-02-09 | 2011-08-18 | Universität Bremen | P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth |
| US10159669B2 (en) | 2010-03-02 | 2018-12-25 | Ian H. Chan | Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use |
| PT2550258E (pt) | 2010-03-25 | 2015-11-30 | Abbvie Inc | Agentes indutores de apoptose para o tratamento de cancro e de doenças imunitárias e autoimunes |
| US8675704B2 (en) | 2010-04-29 | 2014-03-18 | Sri International | Single ridge N-P-N diode laser |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| US20120005765A1 (en) | 2010-07-01 | 2012-01-05 | Saint Louis University | Animal model for parkinson's disease |
| EP2598168A4 (en) * | 2010-07-28 | 2014-03-26 | Merck Sharp & Dohme | COMBINATION THERAPY FOR CANCER TREATMENT WITH AN IGF-1R INHIBITOR AND AN ACT HEMMER |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| US10449177B2 (en) | 2010-08-19 | 2019-10-22 | Buck Institute For Research On Aging | Methods of treating mild cognitive impairment (MCI) and related disorders |
| US9102668B2 (en) | 2010-09-08 | 2015-08-11 | Glaxo Group Limited | Polymorphs and salts |
| WO2012047587A2 (en) | 2010-09-27 | 2012-04-12 | Serrata, Llc | Mdm2 inhibitors for treatment of ocular conditions |
| CA2813256A1 (en) | 2010-09-30 | 2012-04-05 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles |
| FR2966040A1 (fr) | 2010-10-19 | 2012-04-20 | Brigitte Gourlaouen | Composition amincissante et/ou de prevention des processus inflammatoires |
| SG10201801794WA (en) | 2010-10-29 | 2018-04-27 | Abbvie Inc | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| US8741905B2 (en) | 2010-11-05 | 2014-06-03 | The Broad Institute, Inc. | Compounds and methods for treating autoimmune diseases |
| EA201370107A1 (ru) * | 2010-11-11 | 2013-11-29 | Редкс Фарма Лимитед | Производные лекарственных средств |
| US10822374B2 (en) | 2010-11-12 | 2020-11-03 | Dana-Farber Cancer Institute, Inc. | Cancer therapies and diagnostics |
| PE20140408A1 (es) | 2010-11-12 | 2014-04-10 | Univ Michigan | Derivados espiro-oxindol como antagonistas de mdm2 |
| PH12013501006A1 (en) | 2010-11-23 | 2022-03-30 | Abbvie Ireland Unlimited Co | Methods of treatment using selective bcl-2 inhibitors |
| KR101762724B1 (ko) | 2011-01-25 | 2017-07-28 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법 |
| WO2012103524A2 (en) | 2011-01-27 | 2012-08-02 | The Trustees Of Princeton University | Inhibitors of mtor kinasa as anti- viral agents |
| EP2675448B1 (en) * | 2011-01-31 | 2017-01-11 | Tokyo University of Science Foundation | Method of treating ischemia/reperfusion injury |
| BR112013022697A2 (pt) | 2011-03-07 | 2019-09-24 | Fond Telethon | inibidores de fosforilação de tfeb e usos dos mesmos |
| KR101426689B1 (ko) * | 2011-04-19 | 2014-08-08 | 가톨릭대학교 산학협력단 | Ｎｕｔｌｉｎ３ａ 화합물을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 |
| TWI497333B (zh) | 2011-06-14 | 2015-08-21 | Giant Mfg Co Ltd | 自行車適配產生方法、自行車適配系統與電腦程式產品 |
| US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| US20140328893A1 (en) | 2011-10-11 | 2014-11-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nutlin compounds for use in the treatment of pulmonary hypertension |
| US8940737B2 (en) | 2011-10-14 | 2015-01-27 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9140213B2 (en) * | 2011-12-06 | 2015-09-22 | United Technologies Corporation | Leaf spring damper for a turbine engine fuel delivery system |
| RU2014128010A (ru) | 2011-12-13 | 2016-02-10 | Бак Инститьют Фо Рисерч Он Эйджин | Способы улучшения средств консервативной терапии |
| US8747112B2 (en) | 2011-12-30 | 2014-06-10 | Nobel Biocare Services Ag | Abutment position locator |
| AU2013218148A1 (en) | 2012-02-06 | 2014-07-24 | Glaxosmithkline Intellectual Property (No. 2) Limited | PI3K inhibitors for treating fibrotic diseases |
| WO2013155077A1 (en) | 2012-04-09 | 2013-10-17 | Board Of Regents,The University Of Texas System | Response markers for src inhibitor therapies |
| JP2015522528A (ja) | 2012-05-09 | 2015-08-06 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 慢性閉塞性肺疾患の予防または治療方法および医薬組成物 |
| KR101725571B1 (ko) | 2012-06-13 | 2017-04-11 | 가톨릭대학교 산학협력단 | Ｍｄｍ２ 억제제를 유효성분으로 포함하는 노화 억제용 조성물 |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| EP2882439B1 (en) | 2012-08-13 | 2018-04-11 | AbbVie Inc. | Apoptosis-inducing agents |
| US9104666B2 (en) | 2012-09-04 | 2015-08-11 | Oracle International Corporation | Controlling access to a large number of electronic resources |
| RU2637309C2 (ru) | 2012-10-10 | 2017-12-04 | Ф. Хоффманн-Ля Рош Аг | Способ получения соединений тиенопиримидина |
| NZ709635A (en) | 2013-01-16 | 2019-10-25 | Univ Michigan | Bcl-2bcl-xl inhibitors and therapeutic methods using the same |
| FI3922241T3 (fi) | 2013-02-01 | 2023-11-28 | Celator Pharmaceuticals Inc | Niukasti liukoisten lääkkeiden etälataus liposomeihin |
| WO2014137946A1 (en) | 2013-03-04 | 2014-09-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods of inhibiting igf-1r activation or downtream signalling thereof to reduce radiation-induced cellular senescence |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| ES2993671T3 (en) * | 2013-03-15 | 2025-01-03 | Univ Texas | Peptide fttftvt for use in treating fibrosis |
| US20140272947A1 (en) | 2013-03-15 | 2014-09-18 | Fox Chase Cancer Center | Methods and compositions for screening modulators of oncogene-induced senescence |
| RU2015149680A (ru) | 2013-04-21 | 2017-05-24 | Йеда Ресеарч Энд Девелопмент Ко. Лтд. | Агенты для подавления активности и/или снижения количества bcl-xl и/или bcl-w |
| CA2927309A1 (en) | 2013-05-24 | 2014-11-27 | Promis Neurosciences Inc. | Fasr antibodies for diagnostic and therapeutic use |
| TW201536324A (zh) | 2013-06-19 | 2015-10-01 | Buck Inst For Res On Aging | 增加醫藥療法有效性之方法 |
| US20160022720A1 (en) | 2013-08-02 | 2016-01-28 | Children's Hospital Medical Center | Compositions and methods for treating disease states associated with activated t cells and/or b cells |
| WO2015051252A1 (en) | 2013-10-03 | 2015-04-09 | Duke University | Compositions and methods for treating cancer with jak2 activity |
| RU2016104927A (ru) | 2013-11-01 | 2017-12-06 | Эверон Байосайенсис, Инк. | Молекулярные мишени для селективного уничтожения сенесцентных клеток |
| EP3068435A1 (en) | 2013-11-13 | 2016-09-21 | Novartis AG | Mtor inhibitors for enhancing the immune response |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| SG11201606239UA (en) | 2014-01-28 | 2016-08-30 | Buck Inst For Res On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20190000846A1 (en) | 2014-01-28 | 2019-01-03 | Mayo Foundation For Medical Education And Research | Pharmaceutical Products and Drug Combinations for Treating Atherosclerosis by Stabilizing Atherosclerotic Plaques and Promoting Plaque Regression |
| CN106456699B (zh) | 2014-05-05 | 2021-07-02 | 生物风险投资有限责任公司 | 作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法 |
| GB201409519D0 (en) | 2014-05-29 | 2014-07-16 | Univ Leicester | Senescent cell biomarkers |
| CA2981753A1 (en) | 2015-02-06 | 2016-08-11 | Unity Biotechnology, Inc. | Compounds and uses in treatment of senescence-associated conditions |
| US20180000816A1 (en) | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
-
2015
- 2015-01-28 SG SG11201606239UA patent/SG11201606239UA/en unknown
- 2015-01-28 IL IL311537A patent/IL311537A/en unknown
- 2015-01-28 AU AU2015211021A patent/AU2015211021B2/en not_active Ceased
- 2015-01-28 CA CA3100140A patent/CA3100140C/en active Active
- 2015-01-28 IL IL286427A patent/IL286427B2/en unknown
- 2015-01-28 CN CN202010556478.8A patent/CN112274641A/zh active Pending
- 2015-01-28 MX MX2016009753A patent/MX2016009753A/es unknown
- 2015-01-28 CN CN201910589846.6A patent/CN110623956A/zh active Pending
- 2015-01-28 EP EP19216214.7A patent/EP3669881B1/en active Active
- 2015-01-28 WO PCT/US2015/013387 patent/WO2015116740A1/en not_active Ceased
- 2015-01-28 RU RU2016134429A patent/RU2716256C2/ru active
- 2015-01-28 EP EP15743068.7A patent/EP3099380B1/en active Active
- 2015-01-28 SG SG10201805670QA patent/SG10201805670QA/en unknown
- 2015-01-28 KR KR1020167023680A patent/KR102496146B1/ko active Active
- 2015-01-28 BR BR112016017564A patent/BR112016017564A8/pt not_active Application Discontinuation
- 2015-01-28 CN CN201580017167.1A patent/CN106163557B/zh not_active Expired - Fee Related
- 2015-01-28 US US15/114,762 patent/US9993472B2/en active Active
- 2015-01-28 NZ NZ723035A patent/NZ723035A/en unknown
- 2015-01-28 CA CA2939121A patent/CA2939121C/en active Active
- 2015-01-28 JP JP2016549442A patent/JP6688224B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-26 IL IL246954A patent/IL246954B/en unknown
- 2016-07-27 MX MX2021012547A patent/MX2021012547A/es unknown
-
2017
- 2017-03-10 US US15/455,684 patent/US10213426B2/en active Active
- 2017-03-10 US US15/455,575 patent/US9849128B2/en active Active
- 2017-03-10 US US15/455,630 patent/US20170196858A1/en not_active Abandoned
- 2017-03-23 US US15/467,129 patent/US9855266B2/en active Active
- 2017-04-06 US US15/481,129 patent/US10130628B2/en active Active
- 2017-07-12 US US15/647,688 patent/US9980962B2/en active Active
- 2017-11-30 US US15/827,539 patent/US10010546B2/en active Active
-
2018
- 2018-04-11 US US15/950,965 patent/US10413542B2/en active Active
- 2018-04-17 US US15/955,542 patent/US10258618B2/en not_active Expired - Fee Related
- 2018-04-18 US US15/956,613 patent/US10478432B2/en active Active
- 2018-05-16 US US15/981,696 patent/US10517866B2/en active Active
- 2018-06-13 US US16/007,880 patent/US10478433B2/en active Active
- 2018-08-03 US US16/054,667 patent/US10328073B2/en active Active
-
2019
- 2019-04-25 JP JP2019083555A patent/JP2019142933A/ja active Pending
- 2019-07-10 US US16/508,119 patent/US20190343832A1/en not_active Abandoned
- 2019-09-26 US US16/584,638 patent/US11351167B2/en active Active
-
2020
- 2020-03-06 JP JP2020038529A patent/JP2020105213A/ja not_active Withdrawn
- 2020-10-02 AU AU2020244600A patent/AU2020244600A1/en not_active Abandoned
- 2020-10-08 US US17/066,256 patent/US20210030752A1/en active Pending
- 2020-12-07 US US17/114,376 patent/US11963957B2/en active Active
- 2020-12-07 US US17/114,379 patent/US11980616B2/en active Active
-
2021
- 2021-05-13 JP JP2021081356A patent/JP2021138712A/ja active Pending
-
2022
- 2022-10-20 AU AU2022256167A patent/AU2022256167B2/en active Active
-
2023
- 2023-07-05 JP JP2023110762A patent/JP2023126918A/ja active Pending
-
2025
- 2025-02-20 AU AU2025201216A patent/AU2025201216A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017532285A5 (cg-RX-API-DMAC7.html) | ||
| JP7169693B2 (ja) | 呼吸器疾患の治療 | |
| JP6099609B2 (ja) | 肺炎症を低減するためのレボフロキサシンの吸入 | |
| RU2013155903A (ru) | Композиции, способы и устройства для респираторной доставки двух или более активных средств | |
| JP2014528474A5 (cg-RX-API-DMAC7.html) | ||
| JP2008297311A (ja) | 気道疾患の処置のためのプレコナリルを含む薬学的処方物 | |
| JP2008509143A5 (cg-RX-API-DMAC7.html) | ||
| CN102573823A (zh) | 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途 | |
| JP2023532972A (ja) | グルココルチコイド節約剤 | |
| KR20120022751A (ko) | 스테로이드성［３,２?ｃ］피라졸 유도체 및 제２ 제약 활성 화합물을 포함하는 제약 조성물 | |
| Wang et al. | N-methyl-D-aspartate receptor activation mediates lung fibroblast proliferation and differentiation in hyperoxia-induced chronic lung disease in newborn rats | |
| JP2013237709A (ja) | Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬 | |
| JP7433331B2 (ja) | 特発性肺線維症を治療するための組成物及び方法 | |
| JP2020536048A5 (cg-RX-API-DMAC7.html) | ||
| WO2006047427A1 (en) | M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders | |
| JP2021504384A5 (cg-RX-API-DMAC7.html) | ||
| TW200402307A (en) | Nasal composition | |
| US6262077B1 (en) | Composition and method for treating allergic diseases | |
| CN105456265B (zh) | 一种盐酸非索非那定在制备治疗精神分裂症药物中的应用 | |
| CA3095859C (en) | Bambuterol for the treatment of alzheimer's disease | |
| CN102665705A (zh) | 包含非甾体抗炎药和秋水仙碱苷衍生物的活性成分的新组合 | |
| CN106535913A (zh) | 神经活性肽的稳定组合物 | |
| JP2013542262A5 (cg-RX-API-DMAC7.html) | ||
| CN111346058B (zh) | 一种苯二氮䓬类化合物经鼻粘膜给药的药物组合物及其制备方法和用途 | |
| Walker | American Thoracic Society (ATS) 2014 International Conference-San Diego, California, USA-May 16-21, 2014 |